ABX464 — clinical trials using this drug

Public-registry trials using ABX464 that Eichor's radar has found — 2 trials. All data below is from public sources; Eichor is not affiliated with any sponsor.

ABX464 appears in 2 registered trials Eichor's radar has found, sponsored by Abivax S.A., the most recent registered as Phase 3, with a planned enrollment of 639. Registered timeline: 2022–2025. The registry holds 1,879 registered studies for Ulcerative Colitis.

Trial	Sponsor	Condition	Phase	Sites
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1	Abivax S.A.	Ulcerative Colitis	PHASE3	320
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2	Abivax S.A.	Ulcerative Colitis	PHASE3	273

About these studies

ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Status	Completed · planned start 2022-10
Primary completion	2025-06
Enrollment target	639 participants
Design	Randomized · Parallel · Phase 3 · 3 arms
Who it enrolls	All sexes · 16 Years and older — full criteria are on the study record
Locations	320 listed in Argentina, Australia, Austria, Belgium

All fields verbatim from the ClinicalTrials.gov record for NCT05507203.

ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Status	Completed · planned start 2022-12
Primary completion	2025-06
Enrollment target	636 participants
Design	Randomized · Parallel · Phase 3 · 3 arms
Who it enrolls	All sexes · 16 Years and older — full criteria are on the study record
Locations	273 listed in Argentina, Belgium, Brazil, Bulgaria

All fields verbatim from the ClinicalTrials.gov record for NCT05507216.

Registry history

First registered study	May 2015 — NCT02452242 (Abivax S.A.)
Registered studies matching this name	19 all-time · 0 currently recruiting

Source: ClinicalTrials.gov, the public trial registry.

Ulcerative Colitis drug landscape

The public registry holds 1,879 registered studies for Ulcerative Colitis. Compounds appearing across the 200 most recently updated registry entries:

Placebo ×47 Guselkumab ×12 Mirikizumab ×11 Etrasimod ×6 Risankizumab ×5 Vedolizumab ×5 Afimkibart ×4 No intervention ×4 ISM5411 ×3 tofacitinib ×3 Upadacitinib ×3 Ustekinumab ×3 Vedolizumab IV ×3 Vedolizumab SC ×3 AC-101 ×2 Aletekitug ×2 Aquamin ×2 BI 3032950 ×2 Education ×2 Fecal Microbiota Transplantation ×2 Filgotinib ×2 Golimumab ×2 Hemay005 ×2 High ×2 HRS-7085 ×2 Infliximab ×2 INT-210 ×2 JNJ-78934804 ×2 Low ×2 LY4268989 ×2

Free site-risk snapshot for any of these trials

Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Related drugs & trials

Trialed alongside

Placebo

Other Ulcerative Colitis drugs

← Eichor home · All tracked trials · Ulcerative Colitis studies · Weekly briefs

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →